Matching trials
2,411 results
- An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective: Complete Statistical AnalysisIndependent statistical analysis of An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored…
- An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- An Open Label Trial of Bupropion and Naltrexone for Binge Drinking: Complete Statistical AnalysisIndependent statistical analysis of An Open Label Trial of Bupropion and Naltrexone for Binge Drinking: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism: Complete Statistical AnalysisIndependent statistical analysis of An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor: Complete Statistical AnalysisIndependent statistical analysis of An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor: primary endpoint results,…
- An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis: Complete Statistical AnalysisIndependent statistical analysis of An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee: Complete Statistical AnalysisIndependent statistical analysis of An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders: Complete Statistical AnalysisIndependent statistical analysis of An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00308074).
- An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum: Complete Statistical AnalysisIndependent statistical analysis of An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge): Complete Statistical AnalysisIndependent statistical analysis of An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- anaGOIndependent statistical analysis of A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease: Complete Statistical AnalysisIndependent statistical analysis of Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00069329).
- ANCHORIndependent statistical analysis of ANCHOR (NCT03693170), a phase 2 single-group trial of encorafenib, binimetinib and cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer, including its exact binomial response-rate design and statistical…
- ANCHOR-CRCIndependent statistical analysis of Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women: Complete Statistical AnalysisIndependent statistical analysis of Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ANNOUNCE 2Independent statistical analysis of A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04225039).
- Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02597101).
- Anti-LPS Antibody Treatment for Pediatric NAFLD: Complete Statistical AnalysisIndependent statistical analysis of Anti-LPS Antibody Treatment for Pediatric NAFLD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03042767).
- Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection: Complete Statistical AnalysisIndependent statistical analysis of Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection: primary endpoint…
- Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Anti-Tac(90 Y-HAT) to Treat Hodgkin’s Disease, Non-Hodgkin’s Lymphoma and Lymphoid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma: Complete Statistical AnalysisIndependent statistical analysis of Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01112293).
- Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.: Complete Statistical AnalysisIndependent statistical analysis of Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26: Complete Statistical AnalysisIndependent statistical analysis of Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Antidepressant Effects of TS-161 in Treatment-Resistant Depression: Complete Statistical AnalysisIndependent statistical analysis of Antidepressant Effects of TS-161 in Treatment-Resistant Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04821271).
- Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System: Complete Statistical AnalysisIndependent statistical analysis of Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma: Complete Statistical AnalysisIndependent statistical analysis of Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00003508).
- Antineoplaston Therapy in Treating Patients With Meningioma: Complete Statistical AnalysisIndependent statistical analysis of Antineoplaston Therapy in Treating Patients With Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00003483).
- Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer: Complete Statistical AnalysisIndependent statistical analysis of Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- APCGIndependent statistical analysis of Is an Antiplaque Chewing Gum (30 mg) Able to Reduce Dental Plaque in a Healthy Population?: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation: Complete Statistical AnalysisIndependent statistical analysis of Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02889562).
- APOSTLEIndependent statistical analysis of Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03312023).
- APP21Independent statistical analysis of Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- APP22Independent statistical analysis of Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- APPLEIndependent statistical analysis of Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02856893).
- APPOSEIndependent statistical analysis of Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- APPRISE 1Independent statistical analysis of Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- APTIndependent statistical analysis of the APT phase 1/2 study of AP203 in patients with locally advanced or metastatic solid tumors, including trial design, endpoints, planned statistical methods, interpretation, and limitations.
- ARC-7An independent statistical analysis of ARC-7, a randomized phase 2 trial evaluating monotherapy and combination immunotherapies in participants with PD-L1 positive non-small cell lung cancer.
- ARC001Independent statistical analysis of Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- ARDAIndependent statistical analysis of A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy: primary endpoint…
- ART-ADIndependent statistical analysis of Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- ARTS-HFIndependent statistical analysis of the ARTS-HF phase 2 trial of finerenone in worsening chronic heart failure with left ventricular systolic dysfunction and selected diabetes or chronic kidney disease populations.
- ARTSS-2Independent statistical analysis of Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- AS900672-Enriched in Ovulation Induction: Complete Statistical AnalysisIndependent statistical analysis of AS900672-Enriched in Ovulation Induction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00553514).
- ASACIndependent statistical analysis of ASAC (NCT03326791), a randomized phase 2/3 trial evaluating acetylsalicylic acid versus placebo after resection of colorectal cancer liver metastases, with emphasis on disease-free survival and its planned analysis.
- ASCENDIndependent statistical analysis of Assessing Symptomatic Clinical Episodes in Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03595579).
- AscenD-LBIndependent statistical analysis of Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…